Biogen Inc (BIIB)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	1,161,100	1,461,800	2,664,600	3,131,000	3,046,900	2,864,700	2,059,200	1,449,700	1,556,100	1,545,800	1,918,100	3,011,700	4,000,600	5,082,400	5,926,800	5,878,800	5,888,500	5,395,600	5,294,100	4,666,600
Total stockholders’ equity	US$ in thousands	14,799,400	14,483,800	14,466,900	13,796,600	13,397,900	12,775,500	11,872,500	11,242,300	10,896,200	10,429,900	10,751,900	10,682,200	10,700,300	10,758,500	11,308,700	12,546,900	13,343,200	13,995,900	12,952,900	13,829,900
ROE		7.85%	10.09%	18.42%	22.69%	22.74%	22.42%	17.34%	12.90%	14.28%	14.82%	17.84%	28.19%	37.39%	47.24%	52.41%	46.85%	44.13%	38.55%	40.87%	33.74%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,161,100K ÷ $14,799,400K
= 7.85%

Biogen Inc's return on equity (ROE) has shown some fluctuations over the past eight quarters. In Q1 2022, the ROE was 12.90%, which increased to 17.34% in Q2 2022 and further rose to 22.42% in Q3 2022. The ROE peaked at 22.74% in Q4 2022 before experiencing a downward trend in the first half of 2023.

In the latest quarter, Q4 2023, Biogen Inc's ROE was 7.85%, which is lower compared to the previous quarters. This decline could indicate potential challenges in generating profits relative to the shareholders' equity. It is essential for investors and stakeholders to monitor the company's performance closely to understand the factors contributing to the fluctuations in ROE and assess the company's profitability and efficiency in utilizing shareholder funds.